We take a great pleasure in announcing that the Women’s Cancer Initiative- Tata Memorial Hospital (WCI-TMH) and the Association of Gynecologic Oncologists of India (AGOI) are jointly organizing an Annual Conference on Gynecological Cancers from 27th to 29th Oct 2017 at Tata Memorial Hospital, Mumbai.
Established 26 years ago, the Association of Gynecologic oncologists of India (AGOI) is a multidisciplinary professional group of Gynecologic oncologists, Medical oncologists, Surgical oncologists, Radiation oncologists and allied health professionals dedicated to work towards improving outcomes in patients with Gynecological cancers. Currently, AGOI has over 1000 esteemed members.
Women’s Cancer Initiative- Tata Memorial Hospital (WCI-TMH) is a non-governmental organization, established in 2003 at Tata Memorial Hospital, Mumbai. It aims to support patients with Gynecological and Breast cancers and foster continuing education in these treatment disciplines
Established in 1941, the Tata Memorial Hospital (TMH) is India’s leading cancer centre that provides comprehensive cancer care to one and all by the virtue of their motto of Excellence in Service, Education and Research. TMH also plays a leadership role in guiding the national policy and strategy for cancer care by promoting astonishing services through evidence based practice in Oncology, generating evidences through emphasis on research which is affordable, innovative and relevant to the needs of the country. TMH is committed to provide education in cancer for students, trainees, professionals, employees and the public.
The joint conference is the 15th WCI-TMH conference and 25th conference of AGOI. The theme of the conference is ‘’Gynecological Cancers; on the Cusp of Change’’. The theme has been chosen with an aim to highlight the standards of care and cutting edge innovations in Gynecological cancers. We expect that 350-400 delegates from India and abroad.
It is the leading conference in India on the aforementioned subject. Prominent oncologists from India and abroad will share their expert views and relevant evidences on the subject during the conference. The guest faculty for the conference includes internationally renowned researchers and clinicians who have made a global impact on the treatment policies and outcomes for women’s cancers through their extraordinary work.
We welcome you to our joint annual conference on Gynecological cancers where standard management and cutting edge innovations will be presented by key opinion leaders.
We look forward to meet you In Mumbai during the conference.
With Best Regards,
Dr. Sudeep Gupta
Dr. Amita Maheshwari
Dr. Mutch is the Judith and Ira Gall Professor of Obstetrics and Gynecology and the Director of Gynecologic Oncology at the Washington University School of Medicine in St. Louis, Missouri. He is a member of the Division of Gynecologic Oncology of the American Board of Obstetrics and Gynecology, and serves as a reviewer for multiple medical journals related to women’s health and cancers of the female reproductive tract.
Dr. Mutch attended the Washington University School of Medicine, and did his residency training there as well. He underwent fellowship training at Duke University Medical Center before returning to Washington University in 1988. He is a recipient of the Washington University School of Medicine Distinguished Alumni Award and is a member of AOA.
Dr. Mutch has been the recipient of multiple research grants for studies from the American Cancer Society and the National Institutes of Health, among others. He is the Principal Investigator for NRG Oncology at Washington University. Dr. Mutch has authored or co-authored over 280 peer-reviewed publications as well as numerous book chapters on the treatment of cancers of the female reproductive tract. He is currently the PI of an endometrial SPORE (Special Project of Research Excellence) grant and serves as the clinical PI on project 3 which addresses the most efficient and cost effective way to evaluate individuals for inherited disease. He is the PI of the Integrated Translational Genoproteomics Center at Washington University under a U10 grant.
Dr. Mutch is a past president of the Society of Gynecologic Oncology and serves as a member of the FIGO gynecologic oncologic committee and is the co-Chair for the AJCC committee for gynecologic oncology. Dr Mutch has been on both the NCI Uterine Steering committee and the NCI Gynecologic Steering committee and has reviewed projects for both committees.
Dr. Marcela G. del Carmen, MD, MPH is Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and Chief Medical Officer of the Massachusetts General Physicians Organization (MGPO). In that role, she leads over 3,200 MGPO physician members. She graduated from medical school and completed her residency training in gynecology and obstetrics at Johns Hopkins School of Medicine and Hospital and fellowship training in gynecologic oncology at Massachusetts General Hospital. Dr. del Carmen holds a Masters in Public Health from Harvard School of Public Health. She has served on the Ovarian Cancer Committee for the Gynecologic Oncology Group, is a member of the American Board of Obstetrics and Gynecology PROLOG task force, and serves as oral examiner for the American Board of Obstetrics and Gynecology for both general gynecology and gynecologic oncology.
Dr. del Carmen has authored over 160 papers in the peer-reviewed literature and has authored a textbook. Dr. del Carmen is the recipient of numerous teaching and service awards including the National Council on Resident Education in Obstetrics and Gynecology (CREOG) Award, the Howard Ulfelder Teaching Award, the CINE Golden Eagle Award, CBS Cares, and the McGovern Award for Clinical Excellence. Dr. del Carmen’s research focuses on disparities in gynecologic cancer outcomes in underserved minorities and rare gynecologic malignancies.
Dr. William Cliby is an obstetrician-gynecologist in Rochester, Minnesota and is affiliated with Mayo Clinic. He received his medical degree from The Robert Larner, M.D. College of Medicine at The University of Vermont and has been in practice for more than 20 years.
Dr. Saketh Guntupalli is vice-chair for clinical affairs, quality and improvement in the department of obstetrics and gynecology at the University of Colorado School of Medicine. He is board certified in gynecologic oncology and gynecology. He received his undergraduate degree from the Johns Hopkins University and medical degree from the University of Texas at Houston. After completing his residency at Baylor College of Medicine he completed a 3 year fellowship in gynecologic oncology at Washington University in St. Louis. Dr. Guntupalli is the principal investigator (PI) for the Gynecologic Oncology Group (GOG)/NRG research consortium for the University of Colorado and is heavily involved in clinical research.
The following information is provided to guide you through the abstract submission process:
All abstracts must be submitted by email no later than 12th October, 2017. Abstracts will be selected for either Oral or Poster presentation and will receive a confirmation email on or before 20th October, 2017.
Title : Your title should be as concise and accurate as possible. Good titles may ask a question, describe a problem, reference a controversy, summarize an experience, or even state a result.
Aim : State in 1-2 sentences the aim of your study. Describe the scientific context, i.e. why you did the study and include what the hypothesis of the study was. Novelty for its own sake without a clear justification is insufficient reason for a study.
Methods : Briefly state the plan and/or methods used, i.e. how you did the study. For reports of clinical experience it is essential to describe the patient population and how they were identified and / or selected. For comparisons between two populations, it is particularly important to show how the two groups are comparable and / or different.
Results : Clearly summarize the data, i.e. what you found. Use that format which most concisely and clearly presents your results. Abstracts must be complete and include data in the results. Abstracts that do not include results (“results will be presented”) will be automatically rejected.
Conclusions : Briefly state the implications of your findings, i.e. what the results mean.